Compare Oscar Health Inc (OSCR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oscar Health Inc vs GeneDx Holdings Corp — how do they compare? Oscar Health Inc trades at $33.42 (market cap $10.22B), while GeneDx Holdings Corp trades at $67.95 (market cap $2.02B). The key difference: Oscar Health Inc is far larger — about 5.1× GeneDx Holdings Corp's market cap, and Oscar Health Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oscar Health Inc for 15 Days and GeneDx Holdings Corp for 19 Days on average.
| OSCR | WGS | |
|---|---|---|
Market Cap | $10.22B | $2.02B |
Volume | 4,123,394 | 734,640 |
Sector | Health | Health |
52-Week High | $33.81 | $167.51 |
52-Week Low | $10.85 | $34.51 |
Typical Hold Time | 15 Days | 19 Days |
Enterprise Value | $6.57B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OSCR trades at $33.41, up 1.52% today, with a bullish technical signal and strong recent earnings beats in Q1 and Q2 2026. The stock shows robust revenue growth, with 2026 revenue projected at $15.3B and a return to profitability. Analyst sentiment is mixed but leans positive, with a consensus price target of $34.00. Recent news highlights market share gains and raised 2026 guidance, though the stock faces tests from rising medical costs.
The outlook is cautiously optimistic, driven by scalable growth in the ACA market and margin expansion opportunities. Key risks include medical cost pressures and competitive threats. Upside potential exists if the company executes on its 2029 EPS target of $4+, but investors should monitor profitability sustainability amid cost headwinds.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
